Mabqi is proud to announce that its CEO, Sylvain Yon, is attending 2025 BIO International Convention, taking place from June 16 to 19 at the Boston Convention & Exhibition Center.
During this key industry meeting, Mabqi will showcase the latest preclinical results of lead candidate MQI-201, a first in class anti-TRPV6 antibody, new therapeutic solution in oncology.
This event is also an opportunity to discuss our growing portfolio of first-in-class and best-in-class proprietary fully human antibodies, including pH-sensitive antibodies and antibody-drug conjugates (ADCs) & state-of-the-art AI-powered display platform.
This major global event brings together business leaders, researchers, policymakers, investors, and scientists to accelerate biotech innovation. We look forward to engaging with the international biotech community and exploring new opportunities for collaboration and growth.
Feel free to schedule a meeting now on the Bio PartneringTM app.
See you in Boston!
